Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 152

Showing 1-25 of 152 citing articles:

Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 721
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 235
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha, Joo Hyoung Lee, Selvarangan Ponnazhagan
Cancer Research (2020) Vol. 80, Iss. 8, pp. 1615-1623
Open Access | Times Cited: 171
Overcoming Immune Evasion in Melanoma
Kevinn Eddy, Suzie Chen
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 8984-8984
Open Access | Times Cited: 160
Glycosylation: mechanisms, biological functions and clinical implications
Mengyuan He, Xiangxiang Zhou, Xin Wang
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 33
Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.
Shunda Wang, Yatong Li, Xing Cheng, et al.
PubMed (2020) Vol. 10, Iss. 7, pp. 1937-1953
Closed Access | Times Cited: 93
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Zhe Fu, Alexandra M. Mowday, Jeff B. Smaill, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1006-1006
Open Access | Times Cited: 82
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
Manuel Rodrigues, Giulia Vanoni, Pierre Loap, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 34
Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals
Olga O. Krasnovskaya, Daniil Abramchuck, Alexander S. Erofeev, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9154-9154
Open Access | Times Cited: 23
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation
Michael Li, Sherrie Bhoori, Neil Mehta, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 743-755
Closed Access | Times Cited: 15
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Anna Fateeva, Kevinn Eddy, Suzie Chen
Cancers (2024) Vol. 16, Iss. 8, pp. 1571-1571
Open Access | Times Cited: 10
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Rose Ghemrawi, Lama Abuamer, Sedra Kremesh, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2158-2158
Open Access | Times Cited: 10
Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope
Xiaojie Zhang, Bufu Tang, Jinhua Luo, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions
Xiaoyu Gang, Jinshan Yan, Xin Li, et al.
Cancer Letters (2024) Vol. 604, pp. 217241-217241
Open Access | Times Cited: 9
Progress in personalized immunotherapy for patients with brain metastasis
Lalit R. Patel, Nikola Kolundžić, Malak Abedalthagafi
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Developing effective combination therapy for pancreatic cancer: An overview
Aubrey L. Miller, Patrick L. Garcia, Karina J. Yoon
Pharmacological Research (2020) Vol. 155, pp. 104740-104740
Open Access | Times Cited: 56
A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
Kapil Saxena, Shelley M. Herbrich, Naveen Pemmaraju, et al.
Cancer (2021) Vol. 127, Iss. 20, pp. 3761-3771
Open Access | Times Cited: 50
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan, Lingxiang Yu, Ning Zhang, et al.
Cancer Biology and Medicine (2022) Vol. 19, Iss. 6, pp. 1-16
Open Access | Times Cited: 37
Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
Hanwen Wang, Chen Zhao, Cesar A. Santa‐Maria, et al.
iScience (2022) Vol. 25, Iss. 8, pp. 104702-104702
Open Access | Times Cited: 32
Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis
Sebastian Wurster, Nathaniel D. Albert, Uddalak Bharadwaj, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises
Sara Bandini, Paola Ulivi, Tania Rossi
Cells (2024) Vol. 13, Iss. 4, pp. 337-337
Open Access | Times Cited: 7
Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy
Qi Lv, Hongqiong Yang, Dan Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6854-6879
Closed Access | Times Cited: 7
Novel immunotherapies for breast cancer: Focus on 2023 findings
Huanrong Lan, Min Chen, Shi-Ya Yao, et al.
International Immunopharmacology (2024) Vol. 128, pp. 111549-111549
Closed Access | Times Cited: 6
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Giuseppe Luigi Banna, Ornella Cantale, Melissa Bersanelli, et al.
Oncology Reviews (2020) Vol. 14, Iss. 2
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top